We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

News
Category:
Published on:
December 20, 2020

Alira Health is pleased to announce its role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.

Merieux Equity Partners is a global asset manager specialized in the healthcare and nutrition sectors. Cell-Easy is a novel French pharmaceutical laboratory specialized in the development and manufacturing of novel cell therapies for preclinical and clinical studies. This fund raising aims at accelerating the company’s growth in France and internationally, by expanding the Cell-Easy Management Team and strengthening the company’s commercial presence in key regions.

To read the press release on BusinessWire, click here.

For more information, contact Joris Pezzini.

For more information about Alira Health Transaction Advisory services

Click here

Aenean ut neque vehicula, iaculis odio ut, porta risus. In gravida libero faucibus ex vulputate pharetra. Donec sed sapien odio. Donec vel pellentesque eros. Aliquam erat volutpat. Suspendisse luctus massa accumsan, egestas lacus ac, aliquam libero. Praesent mollis magna vel mi fermentum pulvinar. Fusce quis ultricies sapien, eu suscipit ligula. Duis ut enim ac felis scelerisque sodales. Quisque a elit ac mi cursus posuere vitae sed augue. Nunc varius a ex eget posuere. Nullam fringilla aliquet diam. Maecenas mattis ac massa id fermentum. Proin convallis dui sit amet urna volutpat, ac rutrum magna volutpat. Sed gravida tincidunt laoreet. Nulla nec enim vitae nulla vehicula tempus.

Related news

Blog November 17, 2023
Misconceptions About Patient-Centric Co-Design
Many people have misconceptions about patient-centric co-design, and these misconceptions are holding companies back.
Co-Design Digital Health MedTech Patient Centricity Pharma
Blog November 2, 2023
The Impact of New Treatment Approvals in Oncology on Relative Survival Rates for EU Patients
This article explores the relationship between the number of new cancer treatment approvals and the five-year relative survival of cancer patients across the European Union (EU).
Oncology Pharma
Blog October 16, 2023
How to Co-Design a Solution with Patients to Meet Their Needs
To learn how you can benefit from a co-design approach and how to get started, we spoke with two experts on patient engagement and co-design.
Digital Health MedTech Patient Centricity Patient Engagement Pharma
Blog October 9, 2023
Inflation Reduction Act and Pharma – Navigating Uncertainty
What's the impact of the Inflation Reduction Act on small biotechs, mid-size companies and large pharma players, and how can they prepare?
Biotech Pharma
Publications September 19, 2023
Opportunities and Challenges in the Therapeutic and CDMO Markets
Our Transaction Advisory experts have analyzed the CDMO industry trends, M&A activities, and projected growth in this CHEManager article.
CDMO Pharma
News August 31, 2023
Alira Health Named One of the World’s Best Management Consulting Firms by Forbes
Alira Health is proud to announce it has been named by Forbes as one of the World’s Best Management Consulting Firms for 2023.
Life Sciences MedTech Pharma Press Release
Publications August 1, 2023
The EU Pharmaceutical Package: Impact on Orphan Medicinal Products
This article reviews the proposed changes in the EU Pharma Package for data protection related to orphan medicinal products (OMPs).
EU Pharma Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.